Clinical Trials on FGFR Translocations in France

Total 80 results

Centre Leon Berard

Recruiting

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING) (TRacKING)

Cancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditions

France, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
Relay Therapeutics, Inc.

Active, not recruiting

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, Adult

United States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene Amplification

United States, Canada
University Hospital, Montpellier

Unknown

Breakpoint Analysis of de Novo Apparently Balanced Chromosomal Translocations

Balanced Chromosomal Translocation

France
Novartis Pharmaceuticals

Completed

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3 | Squamous Lung Cancer With FGFR1 Amplification | Bladder Cancer With FGFR3 Mutation or Fusion | Advanced Solid Tumors With FGFR1 Amplication | Advanced Solid Tumors With FGFR2 Amplication | Advanced Solid Tumors With FGFR3 Mutation

France, Spain, Taiwan, Germany, Netherlands, Singapore, United States, Australia, Korea, Republic of, Thailand, Israel, Italy, Turkey, Austria
Taiho Oncology, Inc.

Active, not recruiting

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer | FGFR2 Amplification | FGFR 1 High Amplification

Italy, United States, France, United Kingdom, Spain, Portugal, Canada
University Hospital, Montpellier

Completed

Management of Robertsonian Translocation PGT-SR Attempts

Robertsonian Translocation

France
Assistance Publique - Hôpitaux de Paris

Completed

Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion" (TARGET)

Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion | Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion

France
Bristol-Myers Squibb

Completed

MAD Refractory: Solid Tumor QD w/o Break

HER2 or EGFR Expressing Advanced Solid Malignancies

Spain, France
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
Centre Hospitalier Universitaire de Nīmes

Not yet recruiting

Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population (NARCOBIOTE)

Narcolepsy Type 1 | Bacterial Translocation

France
Taiho Oncology, Inc.

Completed

A Study of TAS-120 in Patients With Advanced Solid Tumors

Breast Cancer | Gastric Cancer | Cholangiocarcinoma | Urothelial Cancer | Primary CNS Tumors | Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors

France, United States, Korea, Republic of, United Kingdom, Japan, Hong Kong, Australia, Taiwan, Italy, Canada, Germany, Netherlands, Spain
AstraZeneca

Completed

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients (GLOW)

FGFR Inhibition, Pharmacokinetics, Biomarkers | ER+ Breast Cancer

Czech Republic, Italy, United Kingdom, Hungary, Germany, Romania, Belgium, France
Assistance Publique - Hôpitaux de Paris

Recruiting

A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults (GRAAPH2014)

Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia

France
Assistance Publique - Hôpitaux de Paris

Recruiting

Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults (GRAALL-2014/B)

Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia

France
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) (ROSIE)

Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR L858R | EGFR DEL19

France
Assistance Publique - Hôpitaux de Paris

Completed

Trisomy of Chromosome 21 Diagnosis by High Output Sequencing (SEQ21)

Trisomy 21 - Translocation

France
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

Korea, Republic of, United States, Belgium, Spain, Taiwan, China, United Kingdom, France, Canada, Germany, Thailand, Italy, Portugal, Australia, Puerto Rico
Taiho Oncology, Inc.

Active, not recruiting

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3)

Advanced Cholangiocarcinoma | FGFR2 Gene Rearrangements

United States, Spain, United Kingdom, Australia, Taiwan, Italy, France, Korea, Republic of, Belgium, Japan, Thailand, Germany, Brazil, Peru, Portugal, Argentina, Hong Kong, Mexico, Netherlands, Poland
Assistance Publique - Hôpitaux de Paris

Recruiting

Diagnostic Value of sFlt-1/PlGF Ratio for the Etiology of Intra Uterine Growth Restriction - ANGIOPAG (ANGIOPAG)

Intrauterine Growth Restriction | Fetal Growth Restriction (FGR)

France
Assistance Publique - Hôpitaux de Paris

Completed

Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive (AFR07)

Blast Crisis | Philadelphia Chromosome | Leukemia, Lymphocytic, Acute | Leukemia, Myeloid, Chronic

France
Novartis Pharmaceuticals

Completed

Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase ('MACS1252)

CML in Chronic Phase

Germany, Italy, Spain, Belgium, Croatia, Hungary, Netherlands, Austria, France, Greece, Sweden, Switzerland, Bulgaria, Romania, Slovenia, United Kingdom, Lithuania, Slovakia, Denmark, Finland, Norway, Poland, Czech Republic, Portugal, E... and more
Rennes University Hospital
Novartis; Ministry of Health, France

Completed

Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children (ESPHALL)

Acute Lymphoblastic Leukemia | Philadelphia Chromosome

France
Novartis Pharmaceuticals

Completed

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Germany, Canada, France, Spain, Italy
AstraZeneca

Completed

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC (IFUM)

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Bulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
Puma Biotechnology, Inc.

Terminated

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations (SUMMIT)

Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

France, United States, Spain, Belgium, United Kingdom, Serbia, Australia, Israel, Canada, Denmark, Ireland, Italy, Korea, Republic of
University Medical Center Groningen
Radboud University Medical Center; Maastricht University Medical Center; Erasmus... and other collaborators

Recruiting

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Drug Monitoring | Anaplastic Lymphoma Kinase Gene Mutation | Anaplastic Lymphoma Kinase Gene Translocation

Netherlands, France
Novartis Pharmaceuticals

Completed

An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis

Philadelphia Chromosome Positive CML

United States, Germany, Italy, France
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Terminated

Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis (ARPEGE)

Brain Metastasis | EGFR-mutated Lung Adenocarcinoma

France
Daiichi Sankyo

Active, not recruiting

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

EGFR L858R | EGFR Exon 19 Deletion | Nonsquamous Non-small Cell Lung Cancer

Korea, Republic of, United States, Netherlands, Spain, United Kingdom, Japan, Austria, Belgium, Italy, France, Taiwan, Germany, Australia, Singapore, China, Hong Kong, Norway, Canada, Poland, Portugal, Switzerland
Central Hospital, Nancy, France
Institut de Cancérologie de Lorraine

Enrolling by invitation

Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model (OS-TUMOVASC)

Lung Cancer | Non Small Cell Lung Cancer | Lung Adenocarcinoma | KRAS Mutation-Related Tumors | EGFR Activating Mutation

France
Centre Leon Berard

Active, not recruiting

Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (TIPI)

Philadelphia Chromosome Positive CML | BCR-ABL Positive Chronic Myelogenous Leukemia

France
Groupe Français de Pneumo-Cancérologie

Recruiting

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion (RESAMEX)

Non-small Cell Lung Cancer | EGFR Exon 20 Insertion Mutation

France
Pfizer
Developmental Therapeutics Consortium

Terminated

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

Previously Treated PH + CML

Spain, United States, Austria, Sweden, Germany, France, Italy, Norway
Takeda

Active, not recruiting

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

United States, China, Spain, Australia, Canada, Argentina, Korea, Republic of, Brazil, Japan, Italy, Mexico, France, Greece, Poland, Russian Federation, Austria, Taiwan, Bulgaria, Finland, Turkey
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
Versailles Hospital

Active, not recruiting

Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL (EWALL-INO)

Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)

France
Bristol-Myers Squibb

Completed

Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (START rollover)

Leukemia

Germany, Italy, Korea, Republic of, Sweden, Thailand, United States, Australia, France, Poland, Switzerland, Spain, Ireland, Peru, Brazil, South Africa, Canada, Argentina, Hungary, Finland, Israel, Norway, Russian Federation, United... and more
Novartis Pharmaceuticals

Completed

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Philadelphia Positive Chronic Myeloid Leukemia

United States, Germany, United Kingdom, France, Italy
Novartis Pharmaceuticals

Recruiting

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Myeloid Leukemia, Philadelphia Positive

Korea, Republic of, Germany, France, United States, Greece, Hungary, Italy, Japan, Poland, Russian Federation, Thailand, Turkey, China, Netherlands
Bristol-Myers Squibb

Completed

Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

Chronic Myeloid Leukemia | Philadelphia-Positive Myeloid Leukemia

Belgium, Netherlands, Spain, United States, Italy, Canada, France, Germany, Peru, Singapore, United Kingdom, Australia, Sweden, Finland, Israel, Ireland, Denmark, Korea, Republic of, Norway, Austria, South Africa, Switzerland
Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML

Chronic Myeloid Leukemia

France, United States, Spain, Belgium, Singapore, Poland, Canada, Japan, United Kingdom, Taiwan, Hungary, Germany, Argentina, Russian Federation, Turkey, Colombia, Italy, South Africa, Brazil, Chile, China, Hong Kong, India, Korea, Republic... and more
Bristol-Myers Squibb

Completed

A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (DASISION)

Myeloid Leukemia, Chronic

Germany, India, Japan, Korea, Republic of, Turkey, Chile, China, Spain, Australia, France, Poland, Mexico, Colombia, Belgium, Austria, Italy, Peru, Greece, Brazil, Czech Republic, Hungary, Russian Federation, Netherlands, Argentina, Den... and more
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia | Philadelphia-Positive Myeloid Leukemia

Belgium, Spain, United States, Italy, Argentina, Brazil, Canada, Germany, Peru, Puerto Rico, Singapore, South Africa, Taiwan, United Kingdom, Australia, France, Philippines, Sweden, Thailand, Russian Federation, China, Poland, Finland, Isra... and more
European Organisation for Research and Treatment...

Active, not recruiting

Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (INNOVATION)

Malignant Neoplasm of Stomach | Malignant Neoplasm of Cardio-esophageal Junction of Stomach | Epidermal Growth Factor Receptor (EGFR) Protein Overexpression

Spain, Korea, Republic of, Singapore, Switzerland, Germany, United Kingdom, Italy, France, Estonia, Belgium, Netherlands, Norway, Portugal
Basilea Pharmaceutica

Completed

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01)

Intrahepatic Cholangiocarcinoma | Combined Hepatocellular and Cholangiocarcinoma

Canada, United States, Spain, Belgium, Italy, Korea, Republic of, Germany, Switzerland, France, United Kingdom, Ireland
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

Canada, Italy, United States, United Kingdom, Belgium, Germany, France, Switzerland, Austria, Denmark, Spain, Norway, Sweden, Netherlands, New Zealand, Australia
Goethe University

Completed

Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Philadelphia Chromsome Positive Acute Lymphoblastic Leukemia

Spain, Germany, France
Centre Francois Baclesse
Hoffmann-La Roche; Groupe Français de Pneumo-Cancérologie

Terminated

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR (FLARE)

NSCLC Patients With EGFR Activating Mutation

France
AstraZeneca

Completed

Europe-Japan Diagnostic Study for EGFR Testing (ASSESS)

EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.

Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France

Clinical Trials on FGFR Translocations in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations